Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320140 | 1.00 | MKNK2 (0.47) | MKNK2PDE9ALRRK2ACACBPDE4D | |
| SCHEMBL2320138 | 1.00 | MKNK2 (0.47) | MKNK2PDE9ALRRK2ACACBPDE4D | |
| SCHEMBL5663343 | 0.91 | PDE9A (0.47) | MKNK2PDE9ALRRK2PDE4DPDE10A | |
| SCHEMBL6613792 | 0.80 | CDK4 (0.40) | MKNK2PDE9AACACBPDE10A | |
| SCHEMBL29576081 | 0.76 | EGFR (0.52) | IRAK4 | |
| SCHEMBL29586318 | 0.75 | PDE9A (0.40) | MKNK2PDE9AACACBPDE10A | |
| SCHEMBL29849730 | 0.75 | KDM4E (0.44) | MKNK2LRRK2 | |
| SCHEMBL22264349 | 0.75 | LRRK2 (0.40) | MKNK2LRRK2ACACBGRM5 | |
| SCHEMBL5463861 | 0.74 | HRH4 (0.51) | LRRK2PDE10A | |
| SCHEMBL21554467 | 0.74 | MKNK2 (0.67) | MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | claimed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| CN-115677701-A | Benzo heterocyclic compound and preparation method and application thereof | 昆药集团股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | MKNK2 225/4885PDE9A 4542/4885LRRK2 32/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | MKNK2 619/4885PDE9A 3284/4885LRRK2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.